Agios Pharmaceuticals dropped its next-generation sickle cell drug Tuesday after a failed Phase 2 study. Agios stock tumbled. The post Why Agios Pharma, A Novo Rival, Just Pulled A Bearish Move appeared first on Investor's Business Daily .

General T2AGIO

Motley Fool 3mo ago

Here's Why Agios Pharmaceuticals Stock Soared Today (Hint: It's FDA-Related)

The company received some good news on its most important drug today.

General T3AGIO

Seeking Alpha News 4mo ago

Agios Pharmaceuticals, Inc. (AGIO) Discusses New Data and Strategic Expansion in Rare Hematology at EHA Investor Event - Slideshow

General T2AGIO

Seeking Alpha News 4mo ago

Agios Pharmaceuticals, Inc. (AGIO) Discusses New Data and Strategic Expansion in Rare Hematology at EHA Investor Event Transcript

General T2AGIO

Seeking Alpha News 4mo ago

Agios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic Expansion in Rare Hematology Transcript

General T2AGIO

Seeking Alpha News 4mo ago

Agios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic Expansion in Rare Hematology - Slideshow

General T2AGIO

Motley Fool 5mo ago

Here's Why Shares in Agios Pharmaceuticals Soared This Week (And What to Expect Next in 2026)

The company faces competitive pressure from Novo Nordisk, but it's growing sales from its existing approved drugs and has an exciting drug in its pipeline.

General T3AGIO NVO

AGIO news alerts

Get an alert by email or push when a new headline mentions AGIO.

More news

News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.